At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about which data he is most excited to see for patients with myelofibrosis.
There are important drugs that we’re seeing in essential thrombocythemia and polycythemia vera for earlier disease, and it might impact patients with myelofibrosis. Firstly, the data with a long-acting interferon may help to curb the course of myelofibrosis before it evolves. As far as that, we see a drug that’s active both in essential thrombocythemia and in a myelofibrosis, which is IMG-7289, an LSD1 inhibitor that may have an impact to better control the platelet counts. That was well presented and may have an impact on the disease, as well as for myelofibrosis, for helping in the second-line setting. I’m excited by the sheer number of candidates we have at the current time, and the maturing phase 3 data in the JAK2 inhibitors as single agents. We have ongoing phase 3 trials that will report out soon with drugs alone or in combination that I think will be impactful.